You can buy or sell ONCY and other stocks, options, ETFs, and crypto commission-free!
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus called REOLYSIN. Read More The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
52 Week High
52 Week Low
Simply Wall StMar 13
How Do Analysts See Oncolytics Biotech Inc. (TSE:ONC) Performing Over The Next Few Years?
Oncolytics Biotech Inc.’s (TSE:ONC) released its most recent earnings update in December 2018, which showed that losses became smaller relative to the prior year’s level – great news for investors Below, I’ve laid out key numbers on how market analysts perceive Oncolytics Biotech’s earnings growth outlook over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the underlying driv...
Seeking AlphaMar 8
Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q4 2018 Results - Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2018 Results Earnings Conference Call March 8, 2019 8:30 AM ET Company Participants Michael Moore - VP of IR & Corporate Communications Matthew Coffey - President, CEO Kirk Look - CFO Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good morning. My name is Michelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oncolytics Biotech Fourth Quarter Results Conference Call. All lines have ...
Stock Price, News, & Analysis for Oncolytics Biotech
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck Scho...
-$0.28 per share